BIOMAT Database Logo BIOMAT Database Logo

[Clinical trial with a combination of 150 mcg of d-norgestrel and 30 mcg of ethinylestradiol. Its metabolic effects]. 1976

A V Moggia, and E Koremblit, and A Beauquis

UI MeSH Term Description Entries
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D010060 Ovulation The discharge of an OVUM from a rupturing follicle in the OVARY. Ovulations
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A V Moggia, and E Koremblit, and A Beauquis
[Clinical study of a new mini-dosed estro-progestative combination (30 mcg of ethinyl estradiol and 150 mcg of D-norgestrel)].
February 1975, Semaine des hopitaux. Therapeutique,
A V Moggia, and E Koremblit, and A Beauquis
Clinical and metabolic effects of a pill containing 30 mcg ethinylestradiol plus 75 mcg gestodene.
December 1989, Contraception,
A V Moggia, and E Koremblit, and A Beauquis
Effects of daily 30 mcg d-norgestrel on growth hormone and cortisol.
July 1983, Contraception,
A V Moggia, and E Koremblit, and A Beauquis
Metabolic effects of a combination of dl-norgestrel and ethinylestradiol in humans.
June 1973, Arzneimittel-Forschung,
A V Moggia, and E Koremblit, and A Beauquis
Effects of ethinylestradiol/D-norgestrel combinations on serum lipoproteins.
January 1980, Acta obstetricia et gynecologica Scandinavica,
A V Moggia, and E Koremblit, and A Beauquis
[The 20 mcg ethinylestradiol and 150 mcg desogestrel pill: six month, multicenter study in 235 women].
June 1990, Fertilite, contraception, sexualite,
A V Moggia, and E Koremblit, and A Beauquis
Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two danazol regimens.
December 1990, European journal of obstetrics, gynecology, and reproductive biology,
A V Moggia, and E Koremblit, and A Beauquis
A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon).
June 1994, Malaysian journal of reproductive health : a publication of the Reproductive Research Centre of the National Population and Family Development Board, Malaysia,
A V Moggia, and E Koremblit, and A Beauquis
Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
March 1987, Contraception,
A V Moggia, and E Koremblit, and A Beauquis
Effects of daily 30 MCG norgestrel on glucose, insulin, cholesterol and triglycerides during 1 year's time of use.
June 1983, Asia-Oceania journal of obstetrics and gynaecology,
Copied contents to your clipboard!